FTC’s Largest Pharmaceutical Divestiture Gives Insight into Broader Theories of Harm

By | Antitrust Alert | October 12, 2016

In pharmaceutical transactions involving generic products, the Federal Trade Commission (FTC) has typically focused on narrow antitrust theories of harm and applied a narrow product market analysis often limited to a treatment for a particular indication (and sometimes to a specific mechanism of action).

Tweet Like LinkedIn LinkedIn Google Plus